Auris Medical Provides Business Update
Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises AM-301 program progressing towards clinical and
Read moreNet cash inflow of $13.4 million from recent registered direct offering and warrant exercises AM-301 program progressing towards clinical and
Read moreHamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that
Read moreHamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated
Read moreHamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated
Read moreUp to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001) Results suggest potential for AM-301 nasal spray
Read moreUp to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001) Results suggest potential for AM-301 nasal spray
Read moreUp to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001) Results suggest potential for AM-301 nasal spray
Read moreUp to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001) Results suggest potential for AM-301 nasal spray
Read moreHamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that
Read moreHamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that
Read more